Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Apr 11;53(4):1801660.
doi: 10.1183/13993003.01660-2018. Print 2019 Apr.

Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests

Collaborators, Affiliations
Comparative Study

Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests

Marko Topalovic et al. Eur Respir J. .

Abstract

The interpretation of pulmonary function tests (PFTs) to diagnose respiratory diseases is built on expert opinion that relies on the recognition of patterns and the clinical context for detection of specific diseases. In this study, we aimed to explore the accuracy and interrater variability of pulmonologists when interpreting PFTs compared with artificial intelligence (AI)-based software that was developed and validated in more than 1500 historical patient cases.120 pulmonologists from 16 European hospitals evaluated 50 cases with PFT and clinical information, resulting in 6000 independent interpretations. The AI software examined the same data. American Thoracic Society/European Respiratory Society guidelines were used as the gold standard for PFT pattern interpretation. The gold standard for diagnosis was derived from clinical history, PFT and all additional tests.The pattern recognition of PFTs by pulmonologists (senior 73%, junior 27%) matched the guidelines in 74.4±5.9% of the cases (range 56-88%). The interrater variability of κ=0.67 pointed to a common agreement. Pulmonologists made correct diagnoses in 44.6±8.7% of the cases (range 24-62%) with a large interrater variability (κ=0.35). The AI-based software perfectly matched the PFT pattern interpretations (100%) and assigned a correct diagnosis in 82% of all cases (p<0.0001 for both measures).The interpretation of PFTs by pulmonologists leads to marked variations and errors. AI-based software provides more accurate interpretations and may serve as a powerful decision support tool to improve clinical practice.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Topalovic has nothing to disclose. Conflict of interest: N. Das has nothing to disclose. Conflict of interest: P-R. Burgel reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Teva and Vertex, outside the submitted work. Conflict of interest: M. Daenen has nothing to disclose. Conflict of interest: E. Derom has nothing to disclose. Conflict of interest: C. Haenebalcke reports personal fees from Novartis, Chiesi, GSK and AstraZeneca, outside the submitted work. Conflict of interest: R. Janssen has nothing to disclose. Conflict of interest: H.A.M. Kerstjens has nothing to disclose. Conflict of interest: G. Liistro has nothing to disclose. Conflict of interest: R. Louis reports grants and personal fees from GSK and Novartis, personal fees from AstraZeneca, and grants from Chiesi, outside the submitted work. Conflict of interest: V. Ninane has nothing to disclose. Conflict of interest: C. Pison has nothing to disclose. Conflict of interest: M. Schlesser has nothing to disclose. Conflict of interest: P. Vercauter has nothing to disclose. Conflict of interest: C.F. Vogelmeier reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Grifols, Mundipharma, Novartis and Takeda, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work. Conflict of interest: E. Wouters reports personal fees for board membership from Nycomed and Boehringer, grants from AstraZeneca and GSK, and personal fees for lectures from AstraZeneca, GSK, Novartis and Chiesi, outside the submitted work. Conflict of interest: J. Wynants has nothing to disclose. Conflict of interest: W. Janssens has nothing to disclose.

Comment in

Publication types